Personalized Diagnostics

"It's actually a good thing from an economics standpoint..." Dr. Roger Klein on whether falling prices can help spur innovation

“I’m going to have to present a counter view. I think no. These types of tests are going to be commoditized as more providers come into the space.” Roger Klein, MD, JD on if diagnostics providers are going to be able to capture value in the liquid biopsy market

Are we spiraling to the bottom? Is there any hope for value-based pricing in diagnostics?

Roger D. Klein MD, JD, FCAP is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology (AMP) Solid Tumors Division. A physician and an attorney, Dr Klein served as an expert and key spokesperson in the lawsuit “Association for Molecular Pathology v. Myriad Genetics, Inc.” in which the U.S. Supreme Court invalidated patents on breast cancer genes. He is a leading authority on public policies related to the implementation of precision medicine.

Roger D. Klein, MD JD is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology’s (AMP’s) Solid Tumors Division. A physician and an attorney, Dr Klein served as an expert and key spokesperson in the lawsuit “Association for Molecular Pathology v. Myriad Genetics, Inc.” in which the U.S. Supreme Court invalidated patents on breast cancer genes.

How exactly are molecular diagnostic tests reimbursed?

Is our current coding and reimbursement system up to the task?

How does a new test achieve reimbursement?

Roger D. Klein, MD JD is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology’s (AMP’s) Solid Tumors Division. A physician and an attorney, Dr Klein served as an expert and key spokesperson in the lawsuit “Association for Molecular Pathology v. Myriad Genetics, Inc.” in which the U.S. Supreme Court invalidated patents on breast cancer genes.

Can we bridge the cultural gap between health tech and health care? What happens when "fail fast, fail often " and "move quickly and break things" meets patient care?

Dr. Jill Hagenkord, the co-founder of MDisrupt and previous Chief Medical Officer at Complete Genomics, Invitae, 23 and Me and Color Genomics joins us.

"We're going to have to make it more patient-centric in the very near future."

"Think of the difference we could make in healthcare."

The culture clash between tech and healthcare

Welcome to the Personalized Diagnostics Podcast.

In the upcoming weeks we are going to be talking to some of the greatest minds and personalities in the diagnostics space – the engine which is driving personalized medicine forward.

Thanks for listening.